The technology provided herein relates to novel human cytolytic fusion proteins (hCFPs) suitable to induce apoptosis in human cells comprising a target cell specific binding component and a human effector domain wherein the binding component comprises an antibody or an antibody fragment with an antigen binding site for binding to the cellular surface receptor CD64 and the effector domain comprises a variant of wild type human angiogenin (Ang) or a functional fragment thereof to nucleic acid molecules encoding said recombinant hCFPs vectors and host cells containing said nucleic acids and methods for preparation and producing these hCFPs.
